Shionogi direct mailers misleading, FDA says
Pharma Compliance Alert, November 26, 2008
Shionogi USA Inc.’s Professional NDC Sheet and a Cardinal Health NDC Sheet (direct mailers) for Cedax omit and minimize risks associated with the product, according to an FDA warning letter.
The direct mailers are misleading because they present numerous efficacy claims for Cedax but fail to reveal material risk information associated with use of the drug, and suggest Cedax is effective in a broader range of conditions than has been demonstrated by substantial evidence or substantial clinical experience.
Comments
0 comments on “Shionogi direct mailers misleading, FDA says ”
Related Products
-
ePharm5 InDepth
EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...
-
Healthcare Marketing Advisor
Healthcare Marketing Advisor provides concise, time-saving strategies for branding, promoting, and advertising your...
-
The Complete Guide to Hospital Marketing, Second Edition
The Complete Guide to Hospital Marketing, Second Edition looks at the complex field of healthcare marketing in a...
-
Complete Guide to Lab Safety, 3rd Ed.
The third edition of this popular resource makes training and compliance easier by consolidating regulations from all...
-
Boost Market Share with Your Oncology Services
Join HealthLeaders Media for this 90-minute Webcast, including Q&A and a case study, for valuable lessons from marketing...
Most Popular
- Articles
-
- Note from Hugh
- CMS seeks comment on quality measures
- Note from the instructor: OIG report on usage of financial liability "G" modifiers
- CMS releases new QAPI resources
- HIPAA Q&A: Receiving faxed HEDIS requests
- Remind your workforce members to ’zip their lips’ when it comes to patient privacy
- Q/A: How do we report therapy G codes and modifiers for multiple therapies?
- CMS says it's not too late to avoid payment adjustments
- Documentation of medical necessity drives successful RA appeals
- Recent Recovery Auditor activity
- E-mailed
-
- Note from the instructor: OIG report on usage of financial liability "G" modifiers
- Q/A: How do we report therapy G codes and modifiers for multiple therapies?
- HIPAA Q&A: Receiving faxed HEDIS requests
- CMS says it's not too late to avoid payment adjustments
- FDA makes new proposal related to C. diff and other threatening pathogens
- Eyes see more ICD-10-CM codes because of laterality
- News: Study shows increase in observation services
- Product of the week: Optimizing PEPPER in the Audit Environment
- Dangers of reporting costs improperly
- CMS releases new QAPI resources
- Searched